Compounded Tirzepatide and NAD+ Injections Recalled Due to Sterility Concerns

Apothecary Pharma has issued a nationwide recall for 22 vials of compounded tirzepatide and one vial of NAD+ injection. The recall stems from concerns regarding the sterility of these products, though no illnesses or injuries have been reported. These are compounded versions, not FDA-approved brand-name drugs like Mounjaro or Zepbound. The FDA classified this as a Class II recall, indicating a low probability of serious health consequences.